M A Knowles

Summary

Affiliation: Cancer Research UK
Country: UK

Publications

  1. ncbi Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?
    Margaret A Knowles
    Cancer Research UK Clinical Centre, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Carcinogenesis 27:361-73. 2006
  2. ncbi Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder
    Margaret A Knowles
    Division of Cancer Medicine Research, Cancer Research UK Clinical Centre, St James s University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, U K
    Cancer Res 63:7652-6. 2003
  3. ncbi Mutation analysis of the 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer
    Margaret A Knowles
    Cancer Research UK Clinical Centre, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Cancer Lett 225:121-30. 2005
  4. ncbi Tuberous sclerosis complex (TSC) gene involvement in sporadic tumours
    M A Knowles
    Cancer Research UK Clinical Centre, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Biochem Soc Trans 31:597-602. 2003
  5. ncbi Tumor suppressor loci in bladder cancer
    Margaret A Knowles
    Cancer Research UK Clinical Centre, St James s University Hospital, Beckett Street, Leeds, LS9 7TF, United Kingdom
    Front Biosci 12:2233-51. 2007
  6. pmc Somatic mutation of PTEN in bladder carcinoma
    J S Aveyard
    ICRF Cancer Medicine Research Unit, St James s University Hospital, Leeds, UK
    Br J Cancer 80:904-8. 1999
  7. pmc Putative tumour suppressor gene necdin is hypermethylated and mutated in human cancer
    L E De Faveri
    Section of Experimental Oncology, Cancer Research UK Centre, Leeds Institute of Molecular Medicine, St James s University Hospital, Beckett Street, Leeds LS97TF, UK
    Br J Cancer 108:1368-77. 2013
  8. pmc Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner
    E Di Martino
    Cancer Research UK Clinical Centre, Section of Experimental Oncology, Leeds Institute of Molecular Medicine, St James s University Hospital, Leeds, UK
    Oncogene 28:4306-16. 2009
  9. pmc Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification
    C D Hurst
    Cancer Research UK Clinical Centre, Leeds Institute of Molecular Medicine, St James s University Hospital, Leeds, UK
    Oncogene 27:2716-27. 2008
  10. ncbi DBC1 re-expression alters the expression of multiple components of the plasminogen pathway
    J P Louhelainen
    Cancer Research UK Clinical Centre, St James s University Hospital, Leeds, West Yorkshire, UK
    Oncogene 25:2409-19. 2006

Collaborators

Detail Information

Publications60

  1. ncbi Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?
    Margaret A Knowles
    Cancer Research UK Clinical Centre, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Carcinogenesis 27:361-73. 2006
    ..If this is the case, definition of the molecular signature of this pathway and improved understanding of the biological consequences of the events involved will be pivotal in disease management...
  2. ncbi Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder
    Margaret A Knowles
    Division of Cancer Medicine Research, Cancer Research UK Clinical Centre, St James s University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, U K
    Cancer Res 63:7652-6. 2003
    ..This may indicate that haploinsufficiency for TSC1 can contribute to the development of bladder cancer and, if so, that the LOH of TSC1 observed in >50% of TCCs is biologically significant...
  3. ncbi Mutation analysis of the 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer
    Margaret A Knowles
    Cancer Research UK Clinical Centre, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Cancer Lett 225:121-30. 2005
    ....
  4. ncbi Tuberous sclerosis complex (TSC) gene involvement in sporadic tumours
    M A Knowles
    Cancer Research UK Clinical Centre, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Biochem Soc Trans 31:597-602. 2003
    ..In ovarian and gall bladder carcinoma and non-small-cell carcinoma of the lung, deletions in both 16p13 and 9q34 are found at significant frequency. Mutation analyses in such tumours are now merited...
  5. ncbi Tumor suppressor loci in bladder cancer
    Margaret A Knowles
    Cancer Research UK Clinical Centre, St James s University Hospital, Beckett Street, Leeds, LS9 7TF, United Kingdom
    Front Biosci 12:2233-51. 2007
    ....
  6. pmc Somatic mutation of PTEN in bladder carcinoma
    J S Aveyard
    ICRF Cancer Medicine Research Unit, St James s University Hospital, Leeds, UK
    Br J Cancer 80:904-8. 1999
    ....
  7. pmc Putative tumour suppressor gene necdin is hypermethylated and mutated in human cancer
    L E De Faveri
    Section of Experimental Oncology, Cancer Research UK Centre, Leeds Institute of Molecular Medicine, St James s University Hospital, Beckett Street, Leeds LS97TF, UK
    Br J Cancer 108:1368-77. 2013
    ..Telomerase-immortalised normal human urothelial cells have no detected genetic alterations. Accordingly, many of the genes whose expression is altered following immortalisation are those for which epigenetic silencing is reported...
  8. pmc Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner
    E Di Martino
    Cancer Research UK Clinical Centre, Section of Experimental Oncology, Leeds Institute of Molecular Medicine, St James s University Hospital, Leeds, UK
    Oncogene 28:4306-16. 2009
    ..Our results indicate that the effects of mutant FGFR3 are both cell type specific and mutation specific. Mutant FGFR3 may confer a selective advantage in the urothelium by overcoming normal contact inhibition of proliferation...
  9. pmc Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification
    C D Hurst
    Cancer Research UK Clinical Centre, Leeds Institute of Molecular Medicine, St James s University Hospital, Leeds, UK
    Oncogene 27:2716-27. 2008
    ..Indeed, a phospho-specific Rb antibody showed much Rb protein in a hyperphosphorylated (inactive) form. We conclude that inactivation of the Rb pathway is required in addition to E2F3 overexpression in this subset of bladder tumours...
  10. ncbi DBC1 re-expression alters the expression of multiple components of the plasminogen pathway
    J P Louhelainen
    Cancer Research UK Clinical Centre, St James s University Hospital, Leeds, West Yorkshire, UK
    Oncogene 25:2409-19. 2006
    ..The expression levels of SERPINB5, PLAU, PLAUR and MT1 correlated with the DBC1 levels, suggesting previously unknown involvement of DBC1 in the urokinase-plasminogen pathway...
  11. pmc What we could do now: molecular pathology of bladder cancer
    M A Knowles
    ICRF Clinical Centre in Leeds, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Mol Pathol 54:215-21. 2001
    ..Whereas the latter is not in doubt, present funding for this type of translational research is inadequate...
  12. ncbi Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours
    K Sibley
    ICRF Clinical Centre, St James s University Hospital, Leeds, LS9 7TF, UK
    Oncogene 20:4416-8. 2001
    ..Several tumour types appear not to possess any mutations in FGFR3, suggesting that these mutations are important only in the development of certain types of tumour...
  13. ncbi Negative regulation of G(1)/S transition by the candidate bladder tumour suppressor gene DBCCR1
    H Nishiyama
    ICRF Clinical Centre, St James s University Hospital, Beckett Street, Leeds, LS9 7TF, UK
    Oncogene 20:2956-64. 2001
    ..The levels of apoptosis were not altered. These results demonstrate a role for DBCCR1 in cell cycle control, thereby supporting the hypothesis that this is the tumour suppressor gene targeted by 9q32-33 deletion in bladder cancer...
  14. pmc Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer
    D C Tomlinson
    Cancer Research UK Clinical Centre, St James s University Hospital, Beckett Street, Leeds, UK
    Oncogene 26:5889-99. 2007
    ..These results indicate that targeted inhibition of S249C FGFR3 may represent a useful therapeutic approach in superficial bladder cancer...
  15. pmc Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo
    F R Lamont
    Cancer Research UK Clinical Centre, Leeds Institute of Molecular Medicine, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Br J Cancer 104:75-82. 2011
    ..Activating mutations of FGFR3 are frequently identified in superficial urothelial carcinoma (UC) and increased expression of FGFR1 and FGFR3 are common in both superficial and invasive UC...
  16. ncbi Homozygous deletion at the 9q32-33 candidate tumor suppressor locus in primary human bladder cancer
    H Nishiyama
    ICRF Cancer Medicine Research Unit, St James s University Hospital, Leeds, U K
    Genes Chromosomes Cancer 26:171-5. 1999
    ..To our knowledge, this is the first report to show homozygous deletion at 9q32-33 in TCC or any other type of human tumor. Genes Chromosomes Cancer 26:171-175, 1999...
  17. ncbi Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway
    E J Chapman
    Cancer Research UK Clinical Centre, St James s University Hospital, Leeds, UK
    Oncogene 25:5037-45. 2006
    ..The production of genetically normal but immortal NHUC lines now provides a valuable platform for experiments to examine the timing and combination of events necessary for UCC tumorigenesis...
  18. doi PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs
    R L Ross
    Cancer Research UK Clinical Centre, Leeds Institute of Molecular Medicine, Section of Experimental Oncology, St James s University Hospital, Leeds, UK
    Oncogene 32:768-76. 2013
    ..Mutant forms of PIK3CA may also stimulate intraepithelial cell movement, which could contribute to spread of cells within the urothelium...
  19. pmc FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer
    D C Tomlinson
    Cancer Research UK Clinical Centre, Leeds Institute of Molecular Medicine, St James s University Hospital, Leeds LS9 7TF, UK
    J Pathol 213:91-8. 2007
    ..This may represent a non-mutant subset of tumours in which FGFR3 signalling contributes to the transformed phenotype and which may benefit from FGFR-targeted therapies...
  20. ncbi Identification of novel bladder tumour suppressor genes
    M A Knowles
    ICRF Cancer Medicine Research Unit, St James s University Hospital, Leeds, UK
    Electrophoresis 20:269-79. 1999
    ..It is anticipated that the identification of the genes and/or genetic regions which are frequently altered in TCC will provide useful tools for diagnosis, prediction of prognosis, patient monitoring and novel therapies...
  21. doi AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K
    J M Askham
    Cancer Research UK Clinical Centre, Leeds Institute of Molecular Medicine, St James s University Hospital, Leeds, UK
    Oncogene 29:150-5. 2010
    ..Enhanced activation of AKT1 when E17K and E49K mutations are in tandem suggests that they can co-operate...
  22. doi Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer
    Fiona M Platt
    Cancer Research UK Clinical Centre, Leeds Institute of Molecular Medicine, United Kingdom
    Clin Cancer Res 15:6008-17. 2009
    ..Our aim was to assess the frequency and distribution of pathway alterations in bladder cancer...
  23. ncbi FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
    Adel H Jebar
    Cancer Research UK Clinical Centre, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Oncogene 24:5218-25. 2005
    ..If these events have biological equivalence, Ras mutant invasive UCC may represent a novel subgroup...
  24. ncbi Cell responses to FGFR3 signalling: growth, differentiation and apoptosis
    Corine G M L'Hôte
    Cancer Research UK Clinical Centre, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Exp Cell Res 304:417-31. 2005
    ..Further understanding of the ability of FGFR3 to trigger different responses depending on cell type and cellular context may lead to treatments for both skeletal dysplasias and cancer...
  25. ncbi High-resolution deletion mapping of 15q13.2-q21.1 in transitional cell carcinoma of the bladder
    Rachael Natrajan
    Division of Cancer Medicine Research, Cancer Research UK Clinical Centre, St James s University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, U K
    Cancer Res 63:7657-62. 2003
    ..1 represents a candidate 15q tumor suppressor gene. Expression analysis of rad51 protein in tumor cell lines revealed variable levels of expression but no significant loss of expression in cell lines with likely 15q LOH...
  26. ncbi Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma
    K Sibley
    ICRF Clinical Centre, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Oncogene 20:686-91. 2001
    ..Tumours with and without LOH at 4p16.3 had mutations in FGFR3 suggesting that these two events are not causally linked. The frequency of FGFR3 mutation indicates that this protein plays an important role in TCC...
  27. ncbi A sequence-ready 840-kb PAC contig spanning the candidate tumor suppressor locus DBC1 on human chromosome 9q32-q33
    H Nishiyama
    ICRF Cancer Medicine Research Unit, St James s University Hospital, Beckett Street, Leeds, LS9 7TF, United Kingdom
    Genomics 59:335-8. 1999
    ..One represented the gene for DBCCR1, a known candidate for DBC1, and the other two were novel. This contig and preliminary expression map form the basis for the identification of the bladder cancer tumor suppressor gene in this region...
  28. ncbi Transcriptional control of the human urothelial-specific gene, uroplakin Ia
    G D Hall
    Cancer Research UK Clinical Centre in Leeds, Cancer Research Building, St James s University Hospital, Beckett Street, Leeds, LS9 7TF, UK
    Biochim Biophys Acta 1729:126-34. 2005
    ..The human uroplakin Ia promoter identified has potential use in future gene therapy strategies to restrict transgene expression to the urothelium...
  29. ncbi Adenovirus-mediated gene therapy for bladder cancer: efficient gene delivery to normal and malignant human urothelial cells in vitro and ex vivo
    J D Chester
    Cancer Research UK Clinical Centre in Leeds, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Gene Ther 10:172-9. 2003
    ..A physical barrier, rather than hCAR status, may be the main determinant of transduction of intact epithelium. Clinical trials of adenovirus-mediated gene therapy for superficial bladder cancer are warranted...
  30. pmc Genes involved in differentiation, stem cell renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial cells
    Emma J Chapman
    Cancer Research UK Clinical Centre, St James s University Hospital, Leeds LS97TF, United Kingdom
    Mol Cancer Res 6:1154-68. 2008
    ..Our data supports the concept of both telomere-based and non-telomere effects of telomerase and provides further rationale for the use of telomerase inhibitors in UC...
  31. pmc Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms
    Louis S Pymar
    Cancer Research UK Clinical Centre in Leeds, Leeds Institute for Molecular Medicine, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Hum Mol Genet 17:2006-17. 2008
    ..We conclude that although TSC1 missense mutations do not play a major role in causation of TSC disease, they represent a significant proportion of somatic loss of function mutations in bladder cancer...
  32. ncbi Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines
    Sarah V Williams
    Imperial Cancer Research Fund Clinical Centre, St James s University Hospital, Leeds, United Kingdom
    Genes Chromosomes Cancer 34:86-96. 2002
    ..A new cell line, DSH1, derived from a pT1G2 transitional cell carcinoma with known homozygous deletion of DBCCR1, is described. This study identifies suitable cell lines for future functional analysis of both CDKN2A and DBCCR1...
  33. ncbi Infrequent mutation of TRAIL receptor 2 (TRAIL-R2/DR5) in transitional cell carcinoma of the bladder with 8p21 loss of heterozygosity
    Jacqui Adams
    Cancer Research UK Clinical Centre, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Cancer Lett 220:137-44. 2005
    ..Our results suggest that if TRAIL-R2 is the target of LOH events in these cancers, inactivation of the remaining allele is by a mechanism other than mutation...
  34. doi Mechanisms of FGFR3 actions in endocrine resistant breast cancer
    D C Tomlinson
    Section of Experimental Oncology, Leeds Institute of Molecular Medicine, St James s University Hospital, Leeds, LS9 7TF, United Kingdom
    Int J Cancer 130:2857-66. 2012
    ..Therefore, we hypothesise that FGFRs could play an integral part, not only in breast cancer development but also in resistance to endocrine-therapy...
  35. pmc Expression of NRG1 and its receptors in human bladder cancer
    J A Forster
    Cancer Research UK Clinical Centre, St James University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Br J Cancer 104:1135-43. 2011
    ..Therapies targeting ERBB2 have shown success in the clinic. However, response is not determined solely by expression of ERBB2. Levels of ERBB3, its preferred heterodimerisation partner and ERBB ligands may also have a role...
  36. pmc Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification
    Joanne S Aveyard
    Cancer Research UK Clinical Centre, St James s University Hospital, Beckett Street, Leeds, LS9 7TF UK
    J Mol Diagn 6:356-65. 2004
    ..We conclude that with appropriate controls RTQ-PCR is a sensitive and robust method to detect copy number changes in tumors even in the presence of contaminating normal cell DNA...
  37. doi Integrated genomic and transcriptional analysis of the in vitro evolution of telomerase-immortalized urothelial cells (TERT-NHUC)
    Emma J Chapman
    Cancer Research UK Clinical Centre, St James s University Hospital, Leeds LS97TF, UK
    Genes Chromosomes Cancer 48:694-710. 2009
    ..Loss of a region on 2q including BOK was identified in UC cell lines and primary tumors. DNER and FRAS1 were identified as potential candidate genes, whose expression is altered independently of the acquisition of any genetic event...
  38. ncbi Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype
    Emma J Chapman
    Cancer Research UK Clinical Centre, St James s University Hospital, Leeds, United Kingdom
    Clin Cancer Res 11:5740-7. 2005
    ..We aimed to address these issues by investigating all possible modes of inactivation and clinicopathologic variables in a single tumor panel...
  39. doi Necdin: a multi functional protein with potential tumor suppressor role?
    Emma J Chapman
    Cancer Research UK Clinical Centre, Section of Experimental Oncology, Leeds Institute of Molecular Medicine, St James s University Hospital, Leeds, United Kingdom
    Mol Carcinog 48:975-81. 2009
    ..Confirmation of NDN as a tumor suppressor may have implications for monitoring of PWS patients and could present a novel cancer therapeutic target...
  40. pmc Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
    Margaret A Knowles
    Cancer Research UK Clinical Centre, Leeds Institute of Molecular Medicine, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Cancer Metastasis Rev 28:305-16. 2009
    ..Co-existence of alterations to several PI3K pathway genes in some bladder tumours indicates that these proteins may have functions that are not related solely to the known canonical pathway...
  41. doi High-resolution analysis of genomic alteration on chromosome arm 8p in urothelial carcinoma
    Sarah V Williams
    Leeds Institute of Molecular Medicine, St James s University Hospital, Leeds, UK
    Genes Chromosomes Cancer 49:642-59. 2010
    ..The region around 2 Mb, which was homozygously deleted in one cell line and includes the gene ARHGEF10 and the micro-RNA hsa-mir-596, is one candidate tumor suppressor gene region...
  42. pmc MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer
    Ananya Choudhury
    Sections of Experimental Oncology and Epidemiology and Biostatistics, Leeds Institute of Molecular Medicine, Cancer Research UK Genome Variation Laboratory Service, Leeds, United Kingdom
    Cancer Res 70:7017-26. 2010
    ..MRE11 expression may ultimately allow patient selection for radiotherapy or cystectomy, thus improving overall cure rates...
  43. doi Papillary and muscle invasive bladder tumors with distinct genomic stability profiles have different DNA repair fidelity and KU DNA-binding activities
    Johanne Bentley
    Cancer Research UK Clinical Centre, Section of Experimental Oncology, Leeds Institute of Molecular Medicine, St James s University Hospital, Leeds, UK
    Genes Chromosomes Cancer 48:310-21. 2009
    ..End-joining fidelity correlated with stage and was increasingly error-prone as tumors became more invasive and KU binding activity reduced; these changes may underlie the different genomic profiles of these tumors...
  44. pmc Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer
    M T W Teo
    Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
    Ann Oncol 25:877-83. 2014
    ..Here, we investigated germline MRE11A variants as possible predictors of RT outcomes in MIBC, using next-generation sequencing (NGS)...
  45. pmc The use of a neutral peptide aptamer scaffold to anchor BH3 peptides constitutes a viable approach to studying their function
    L K J Stadler
    1 Section of Experimental Therapeutics, Leeds LS9 7TF, UK 2 Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UK
    Cell Death Dis 5:e1037. 2014
    ..Finally, the binding of the Bim BH3 peptide to Bax was the only interaction with a pro-apoptotic effector protein observed in this study. ..
  46. ncbi Association between hormonal genetic polymorphisms and early-onset prostate cancer
    M S Forrest
    Cancer Research UK Cancer Medicine Research Division, University of Leeds, Leeds, UK
    Prostate Cancer Prostatic Dis 8:95-102. 2005
    ..49A >T polymorphisms and CaP risk. These findings suggest that common polymorphisms in the AR and SRD5A2 genes may be associated with early-onset CaP in British men...
  47. ncbi High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization
    Carolyn D Hurst
    Cancer Research UK Clinical Centre, St James s University Hospital, Beckett St, Leeds LS9 7TF, UK
    Oncogene 23:2250-63. 2004
    ..3 being the most frequent. Real-time PCR analysis revealed a novel candidate gene with consistent overexpression in all cell lines with the 6p22.3 amplicon...
  48. ncbi Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines
    Darren C Tomlinson
    Cancer Research UK Clinical Centre, St James s University Hospital, Leeds, United Kingdom
    Cancer Res 65:10441-9. 2005
    ..In summary, alternative splicing of FGFR3 IIIb in NHU cells represents a normal mechanism to generate a transcript that regulates proliferation and in bladder cancer, the ratio of FGFR3 isoforms is significantly altered...
  49. ncbi Loss of heterozygosity analysis and DNA copy number measurement on 8p in bladder cancer reveals two mechanisms of allelic loss
    Jacqui Adams
    Cancer Research UK Clinical Centre, St James University Hospital, Leeds, United Kingdom
    Cancer Res 65:66-75. 2005
    ..This implicates both major DNA double-strand break repair mechanisms in the generation of 8p alterations...
  50. pmc DNA double strand break repair in human bladder cancer is error prone and involves microhomology-associated end-joining
    Johanne Bentley
    Cancer Research UK Clinical Centre, St James s University Hospital, Leeds, LS9 7TF, UK
    Nucleic Acids Res 32:5249-59. 2004
    ..Therefore, in high-grade tumours mismatched DSBs are repaired by a highly mutagenic, microhomology-mediated, alternative end-joining pathway, a process that may contribute to genomic instability observed in bladder cancer...
  51. ncbi Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target
    Margaret A Knowles
    Cancer Research UK Clinical Centre, Section of Oncology, Leeds Institute of Molecular Medicine, St James s University Hospital, Beckett Street, Leeds, LS9 7TF, UK
    World J Urol 25:581-93. 2007
    ..This review summarises the current state of knowledge of this interesting receptor in urothelial carcinoma (UC)...
  52. pmc Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma
    Caroline Conway
    Section of Epidemiology and Biostatistics, Leeds Institute of Molecular Medicine, University of Leeds, St James s University Hospital, Leeds, UK
    Genes Chromosomes Cancer 49:425-38. 2010
    ..There was no association between reduced gene dosage at 9p21.3 and subtype or site of tumor. This study presents supportive evidence that CDKN2B, P14ARF, and CDKN2A may all play a tumor suppressor role in melanoma progression...
  53. ncbi Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro
    Sarah V Williams
    Cancer Research UK Clinical Centre, St James s University Hospital, Leeds, UK
    Genes Chromosomes Cancer 43:315-28. 2005
    ..Some changes represented distal loss, whereas others were small deletions. Further study of this region is warranted...
  54. ncbi Fibroblast growth factors and their receptors in transitional cell carcinoma
    Nicholas P Munro
    Cancer Research United Kingdom Clinical Centre in Leeds, St James s University Hospital, Leeds, United Kingdom
    J Urol 169:675-82. 2003
    ..We examined these possibilities in light of the published literature...
  55. pmc Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer
    Darren C Tomlinson
    Cancer Research UK Clinical Centre, Leeds Institute of Molecular Medicine, St James s University Hospital, Leeds, United Kingdom
    Cancer Res 69:4613-20. 2009
    ..Our results indicate that FGFR1 has significant effects on urothelial cell phenotype and may represent a useful therapeutic target in some cases of urothelial carcinoma...
  56. ncbi Molecular pathogenesis of bladder cancer
    Margaret A Knowles
    Cancer Research UK Clinical Centre, Leeds Institute of Molecular Medicine, St James s University Hospital, Beckett Street, Leeds, UK
    Int J Clin Oncol 13:287-97. 2008
    ..The molecular pathogenesis of high-grade noninvasive papillary tumors and of T1 tumors is not yet clear and possibilities are discussed...
  57. ncbi Urinary biomarker profiling in transitional cell carcinoma
    Nicholas P Munro
    Cancer Research UK Clinical Centre, St James s University Hospital, Beckett Street, Leeds, United Kingdom
    Int J Cancer 119:2642-50. 2006
    ..Identification of the relevant peaks may facilitate multiplex marker assay development for detection of recurrent disease...
  58. pmc Identification of genes up-regulated in urothelial tumors: the 67-kd laminin receptor and tumor-associated trypsin inhibitor
    Christine P Diggle
    Cancer Research United Kingdom Clinical Centre, St James s University Hospital, Leeds, UK
    Am J Pathol 163:493-504. 2003
    ....
  59. doi Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors
    Margaret A Knowles
    Cancer Research UK Clinical Centre, Section of Oncology, Leeds Institute of Molecular Medicine, St James s University Hospital, Beckett Street, Leeds, LS9 7TF, UK
    Future Oncol 4:71-83. 2008
    ..Recent preclinical evaluations of FGFR3 as a therapeutic target have provided a strong impetus for the development of targeted agents for clinical use...
  60. ncbi Can p53 staining be used to identify patients with aggressive superficial bladder cancer?
    John R W Masters
    Institute of Urology, University College London, 3rd Floor, 67 Riding House Street, London W1W 7EJ, UK
    J Pathol 200:74-81. 2003
    ....